PMOS is missed unequally

If you have a PCOS diagnosis, what you have is now formally called PMOS (polyendocrine metabolic ovarian syndrome), the new name confirmed by global consensus in May 2026. The diagnostic criteria did not change. The clinical condition did not change. What this article describes (the systematic patterns by which the condition gets missed in specific populations) is unchanged by the rename, and in some respects more visible after it. The 2026 Lancet rename consensus explicitly named diagnostic disparities as one of the problems the broader diagnostic conversation needs to address.

The average time from symptom onset to PMOS diagnosis is over two years. For some women, it is five. For some, more than a decade. The differences are not random; they track along documented lines of race, body size, geography, age, and gender. The evidence is now consistent enough that the 2023 International Guideline names these patterns explicitly and includes specific recommendations to address them.

The documented patterns

These findings have been replicated across multiple studies, multiple countries, and multiple diagnostic frameworks. They are not interpretive claims; they are measured outcomes.

Black women. Higher prevalence of PMOS than the general population, with longer diagnostic delays and a higher rate of being told weight loss is the answer before other workup. Metabolic consequences (type 2 diabetes, hypertension, cardiovascular risk) appear earlier in this population, often before formal PMOS diagnosis. Evidence consistent across multi-cohort observational data from the United States and the United Kingdom.

South Asian women. Higher prevalence of PMOS than Caucasian-European populations, earlier onset, and a more severe metabolic phenotype on average. Frequently undiagnosed because the BMI thresholds used in clinical practice were developed in European cohorts and miss South Asian patients whose insulin resistance and central adiposity are clinically significant at lower BMI values. Some clinical guidelines now recommend South Asian-specific BMI cutoffs (overweight at 23+, not 25+) to address this.

East Asian women.Often present with less prominent hirsutism and lower BMI than the most visually "obvious" PMOS phenotype in standard clinical training. Systematic under-detection when diagnostic suspicion relies on visible hirsutism or elevated BMI as the lead signal.

Women at a lean body weight (any ethnicity). "You don’t look like you have PMOS" remains one of the most common dismissals. Approximately 20 to 25 percent of women with PMOS are at a normal BMI. The 2026 Lancet rename consensus reports approximately 75 percent of women with PMOS at a lean body weight have insulin resistance. The lean PMOS pillar covers this population in depth.

Adolescents. Cycle irregularity in the first two years post-menarche is developmentally typical, which means PMOS-pattern symptoms in this age range are often dismissed as transient. The 2023 International Guideline now explicitly recommends delaying the formal PMOS label in adolescents while not delaying the workup or the supportive care.

Women in low- and middle-income country (LMIC) settings. Access to the ultrasound and hormonal workup required for criterion-based diagnosis is uneven. WHO data suggest many women with PMOS in LMIC settings never receive a formal diagnosis, with consequences for fertility care and downstream metabolic management. The 2026 Lancet rename consensus explicitly called for expanded global access as part of the rationale for naming the condition more precisely.

Trans and non-binary patients. PMOS care pathways assume a cisgender female patient and a cisgender female clinician. Patients who do not present that way often face clinicians who are not equipped to engage with PMOS in their clinical context. This is an emerging area of literature; the evidence base is smaller than for the populations above, but the practical disparity is documented.

A missed diagnosis is not an edge case. For several of these groups, delayed or missed diagnosis is the default experience, and the consequence is measured in years of metabolic risk and emotional weight.

Where the gaps come from

Understanding the structure of the disparities does not fix them; it does show where change is possible.

Diagnostic criteria developed in narrow populations. The Rotterdam criteria (the global standard since 2003) were developed primarily using Caucasian-European cohorts. The BMI thresholds, the Ferriman-Gallwey hirsutism scoring, and the ovarian morphology norms all reflect that. Applied across populations that present PMOS differently, these criteria miss cases. The 2023 Guideline and the 2026 rename consensus both acknowledge this.

Weight-centred gatekeeping.In many clinical settings, a "normal" BMI functions as evidence against PMOS, even though 20 to 25 percent of patients are at a lean body weight. This filters cases out before a workup begins. The mechanism is documented, and the 2023 Guideline addresses it directly.

Time pressure in primary care.A complete PMOS workup requires a careful history (cycles, symptoms, metabolic markers, symptom timing). A 12-minute appointment often does not accommodate that. Symptoms get attributed to stress, weight, or "life," and the workup gets deferred.

Training gaps. Many medical curricula still teach PMOS primarily through its most visible presentation (elevated BMI, prominent hirsutism, anovulatory infertility). Patients outside that phenotype are less likely to be suspected.

Patterns of medical dismissal.Research on medical dismissal consistently shows that Black women’s symptoms and pain reports are taken less seriously on average than white women’s. PMOS is not exempt from this pattern; it shows up in diagnostic delay.

What the current guidelines recommend

The 2023 International Guideline includes explicit acknowledgement of these disparities and specific recommendations. The 2026 Lancet rename consensus reinforces them. The relevant guidance:

• Use ethnicity-appropriate BMI and waist circumference thresholds where validated data exists. South Asian-specific cutoffs are the most clearly established.
• Do not rule out PMOS based on BMI alone. Lean PMOS is named explicitly in both the 2023 Guideline and the 2026 rename consensus.
• Consider PMOS in adolescents with symptoms even when the formal label is deferred. Workup and supportive care should not wait for the diagnostic threshold.
• Use the Ferriman-Gallwey hirsutism score with awareness that the threshold for clinical hirsutism varies across populations. Modified scoring approaches exist for some populations.
• Address mental health and eating-related concerns routinely as part of PMOS care. Disordered eating is more common in PMOS, and weight-focused care without mental health support can deepen rather than resolve the underlying patterns.
• Engage trans and non-binary patients with PMOS care pathways that are not contingent on a cisgender presentation.

These recommendations are the formal global guidance. The gap between guidance and practice is wide; closing it is part of the practical work of equitable PMOS care.

What this means for the next appointment

If you are in one of the populations with documented higher miss rates, or if you have been told you "don’t look like you have PMOS," the research is consistent on the patterns. The current Guideline is consistent on what should be done.

A short written summary to bring to an appointment includes the cycle history, specific symptoms and their timing, family history of PMOS or type 2 diabetes or cardiovascular disease, and any previous labs. A concrete ask:

"Can we run a PMOS workup? I would like fasting insulin (not just glucose), free testosterone with SHBG (not just total testosterone), DHEA-S for adrenal contribution, and a pelvic ultrasound if criteria-based diagnosis requires it."

This is not a demanding ask. It is the standard of care under the 2023 International Guideline. The care-prep guide on PMOS diagnosis covers the full diagnostic workup in detail.

If the response is dismissive (BMI-based gatekeeping, "your cycles will sort themselves out," weight loss as the sole prescription before workup), a second opinion is reasonable. Patient advocacy here is not optional in many practical care contexts; it is part of how the diagnostic gap closes for individual patients.

A note on what is changing

The 2026 PMOS rename was not only a naming change. The consensus process explicitly addressed the diagnostic-criteria-developed-in-narrow-populations problem and called for ongoing work to refine diagnostic standards for populations historically under-represented in the research base. This work is in progress, not complete.

Several active research efforts are particularly relevant to this article: validation of ethnicity-specific diagnostic thresholds, improved adolescent PMOS criteria, gender-inclusive care pathways, and broader access in LMIC settings. The disparities described in this article are still the May 2026 picture. The 2028 Guideline update is expected to refine several of them.